China to fight COVID-19 with Roche arthritis drug

Wednesday, 04. March 2020 08:53

China plans to use Roche Holding AG’s arthritis drug Tocilizumab to treat COVID-19 patients with severe conditions, health authorities said on Wednesday.

In its latest online version of the COVID-19 treatment guidelines, the Chinese National Health Commission said Tocilizumab produced by the Swiss multinational healthcare company Roche Holding and sold under the trade name of Actemra, could be used for the treatment of the patients who are showing signs of serious lung conditions. Nevertheless, Actemra is yet to be approved by China’s National Medical Product Administration since there is no clinical trial evidence yet that proves the drug is effective for the treatment of coronavirus patients.

In the meantime, Chinese pharmaceutical companies are rushing to develop their alternative drug for COVID-19 treatment, which supposed to be a cheaper version of more complex biotech drug Actemra.

Related Links: Roche Holding
Author:
Breaking the News / BJ